Reduction of Long-Term Care Dependence After an 8-Year Primary Care Prevention Program for Stroke and Dementia: The INVADE Trial

Horst Bickel, PhD; Karl-Heinz Ander, MD; Monika Brönner, MD; Thorleif Etgen, MD; Hans Gnahn, MD; Othmar Gotzler, MD; Holger Poppert, MD; Klaus Pürner, MD; Dirk Sander, Professor, MD; Hans Förstl, Professor, MD

Background—Stroke and dementia are the major causes for long-term care (LTC) dependence in old age. This intervention trial compared a multidomain prevention program for stroke and dementia with usual medical care in reducing the need for LTC.

Methods and Results—The Intervention Project on Cerebrovascular Disease and Dementia in the District of Ebersberg (INVADE) was a general practice–based 8-year trial in 2 defined catchment areas in Upper Bavaria, Germany. All 11 317 insurants of a statutory health insurance plan who were ≥55 years of age and lived in the intervention district were offered the opportunity to participate in a prevention program; 3908 enrolled. The 13 301 insurants in the reference district received usual medical care. The intervention consisted of the systematic identification and evidence-based treatment of vascular risk factors. The primary clinical end point was incidence of LTC dependence according to external assessment by a special medical service in the framework of the statutory German LTC insurance. Age- and sex-specific incidence rates from the reference district were used to calculate the expected number of cases of LTC dependence under usual medical care. The expected number was compared with the observed number of cases in the intervention district. Analysis was by intention to treat. During the 5 years after completion of the recruitment period, significantly fewer incident cases of LTC dependence arose in the intervention district than expected (χ² = 13.25; P < 0.001). In women, the incidence was reduced by 10% (P < 0.01). In men, the incidence was reduced by 9.6% (P < 0.05).

Conclusions—Our results support the feasibility and effectiveness of a primary care prevention program for stroke and dementia to reduce the risk of developing LTC dependence.

Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT01107548. (J Am Heart Assoc. 2012;1:e000786 doi: 10.1161/JAHA.112.000786.)

Key Words: stroke • prevention • risk factors • dementia

Stroke and dementia are the leading causes of lasting disability, need for long-term care (LTC), and reliance on nursing homes.1–4 Studies of illness costs show them to be the most expensive diseases of advanced age.5,6 Because the incidence rates of stroke and dementia increase rapidly with advancing age,7–9 a large increase in the number of patients must be expected as a result of the continuous aging of the population unless the risk of these diseases can be reduced by preventive measures.

The INTERSTROKE study found that 90% of stroke risk is determined by 10 risk factors.10 Among the most important modifiable risk factors for stroke, with a high population-attributable risk and a proven preventive effect of their treatment, are arterial hypertension, smoking, diabetes mellitus, atrial fibrillation, and dyslipidemia.11 Other factors, such as obesity, lack of physical activity, alcohol abuse, hyperhomocysteinemia, and depression, are independently associated with the risk of stroke, but there is still a lack of controlled studies that can unequivocally demonstrate that modification of these factors has a preventive effect.11,12

Observational studies from the past 2 decades report connections of dementia with virtually all risk factors that also increase the risk of stroke. Not only the vascular dementias but also the more frequent Alzheimer’s dementia are closely associated with cardiovascular risk factors.13–18 Future dementia can be predicted most accurately by vascular risk factors,19,20 and persons who have a higher stroke risk according to a validated stroke risk scale exhibit more serious
Figure 1. Composition of the study population.

Cognitive deficits.\textsuperscript{21,22} Thus, the evidence for a causal role of cardiovascular risk factors in dementia is strong, but the examination of various preventive strategies has yielded inconsistent results.\textsuperscript{23–25} Against the background of a multifactorial etiology of dementia, experts in the field have been calling for multidomain interventions and a lowering of the vascular risk profile by evidence-based treatment.\textsuperscript{15,17,23,26}

The aim of the present study was to investigate whether the systematic identification and treatment of vascular risk factors, which are amenable to intervention in the primary care setting, can reduce the occurrence of the need for LTC. We chose LTC dependence as the primary clinical end point because this parameter is readily available in Germany as a result of statutory LTC insurance. Under the assumption that stroke and dementia together cause most of the cases of LTC dependence in the population, we hypothesized that an effective prevention program against stroke and dementia would be connected with a reduction of the need for LTC.

**Methods**

**Study Population and Participants**

The Intervention Project on Cerebrovascular Disease and Dementia in the District of Ebersberg (INVADE) is a prevention study at the level of medical primary care in a geographically defined catchment area in Upper Bavaria, Germany. All members of the AOK Bayern (Allgemeine Ortskrankenkasse Bayern) health insurance company who were ≥55 years of age (year of birth ≤1946) and lived in the district of Ebersberg were eligible for the study. The AOK is the largest health insurance company in Germany, with a market share >40% in Bavaria. At the beginning of the study, the district, which is located to the east of Munich, had a total population of nearly 119 000, out of which 11 317 of the insured fulfilled the inclusion criteria at the beginning of the year 2001 (Figure 1).

After they had been invited to participate in writing by their health insurer, a total of 3908 people enrolled in the trial during the recruitment phase, which took place between 2001 and 2003 (Figure 2). The remaining 7409 did not enroll in the trial. In reference to the number of insurants at the outset, a total of 34.5% participated: 33.2% of the men and 35.5% of the women. Among those 55 to 69 years of age, the participation rate was 40.3%; among those 70 to 79 years of age, it was 34.4%; and among those ≥80 years of age, it was 15.9% (Table 1).

**Reference Population**

A cluster randomization of the general practitioner (GP) practices in the study area was not feasible because the insured have the free choice of their doctors in the German healthcare system. In view of the intended study duration of 8 years, a high level of transfer of the insured among the various practices was to be expected, and the offer of an intervention might possibly have increased such patient movement. This would have prevented a comparison of participants and nonparticipants in the intervention program. We therefore decided to compare the intervention district with a second, structurally similar district in Upper Bavaria in which the intervention program was not offered.

As a reference district with usual medical care, the district of Dachau was chosen. At the beginning of 2001, Dachau had a population of 129 500, with 13 301 AOK-insured patients who were born in 1946 or earlier (Table 2). The 2 districts have no common borders, and they are separated by the city of Munich, so it would be unlikely that a patient from one district would receive medical care in the other district. Both districts are rural in character and very similar with regard to area, population, age and sex structure, migration rates,
Prevention of Long-Term Care Dependence  Bickel et al

Figure 2. Flow of participants in the intervention program.

and number of places in nursing homes. With the use of the health insurance company’s data, morbidity and mortality rates were compared between the districts before the beginning of the study. For the year 2000, which preceded the study, morbidity and mortality rates among those insured by the AOK were not significantly different. In the intervention district, 959 prevalent cases of LTC dependence were registered at the end of the year; during the course of the year, 273 incident cases of LTC dependence and 394 deaths had occurred. After age- and sex-specific standardization of the rates of the reference district, 1012 prevalent ($\chi^2=2.78$, $P=0.10$) and 273 incident cases of LTC dependence ($\chi^2=0.0$, $P=0.99$) as well as 426 deaths ($\chi^2=2.40$, $P=0.12$) would have been expected. In the 3 subsequent years, 2001 through 2003, during which the study participants were recruited, the comparability of the 2 districts was confirmed. During this baseline phase, no significant differences in death rate or in the incidence and prevalence of LTC dependence occurred (see Results section).

Assessment of Vascular Risk Factors

Data were obtained at baseline through participants’ self-report, examination by the family doctor, laboratory analyses, and duplex ultrasonography (Table 3). Of the total of 76 GPs and family doctors (designated together as GPs hereafter) who practiced in the district of Ebersberg, 72 (94.7%) participated in the study. The investigation by the GP included a standardized questionnaire, a physical examination, a 12-lead electrocardiogram, and an overnight fasting venous blood sample for analysis in a central laboratory. Cognitive deficits were assessed through the 6-Item Cognitive Impairment Test (6CIT), a short cognitive screening test designed especially for use in general practice.\textsuperscript{28,29} Restrictions of activities of daily living were estimated according to the Rankin Scale\textsuperscript{30} and the Barthel Index.\textsuperscript{31} Fasting blood samples were transferred on ice to a central laboratory that performed all analyses.

Table 1. Number of Participants in the Intervention Program and Number of Insured Persons in the Intervention District at the Beginning of 2001 by Age Group and Sex

| Year of Birth | Participants | Insured Persons |
|---------------|--------------|-----------------|
|               | Men, n       | Women, n        | Men, n | Women, n |
| 1942–1946     | 286          | 357             | 933    | 813      |
| 1937–1941     | 487          | 607             | 1288   | 1261     |
| 1932–1936     | 371          | 444             | 998    | 1043     |
| 1927–1931     | 245          | 388             | 701    | 982      |
| 1922–1926     | 129          | 285             | 447    | 913      |
| 1917–1921     | 57           | 152             | 252    | 698      |
| 1912–1916     | 20           | 63              | 133    | 472      |
| \(\leq 1911\) | 5            | 12              | 72     | 311      |
| \(\leq 1946\) | 1600         | 2308            | 4824   | 6493     |

Table 2. Number of Insured Persons With Birth Year \(\leq 1946\) at the Beginning of the Year 2001 in the 2 Districts, by Age Group and Sex

| Year of Birth | Intervention District | Reference District |
|---------------|-----------------------|-------------------|
|               | Men, n | Women, n | Men, n | Women, n |
| 1942–1946     | 933    | 813      | 1018   | 1180     |
| 1937–1941     | 1288   | 1261     | 1434   | 1428     |
| 1932–1936     | 998    | 1043     | 1054   | 1275     |
| 1927–1931     | 701    | 982      | 829    | 1151     |
| 1922–1926     | 447    | 913      | 526    | 1120     |
| 1917–1921     | 252    | 698      | 277    | 775      |
| 1912–1916     | 133    | 472      | 170    | 622      |
| \(\leq 1911\) | 72     | 311      | 80     | 362      |
| \(\leq 1946\) | 4824   | 6493     | 5388   | 7913     |
Table 3. Data Sources and Study Variables

| Data Source | Study Variables                          |
|-------------|-----------------------------------------|
| Participants’ self-report | Sociodemographic data                      |
|             | Subjective health                          |
|             | Use of medical services                    |
|             | Memory complaints                           |
|             | Depressive symptoms (Geriatric Depression Scale) |
| GP          | History of diseases                        |
|             | Current diseases                            |
|             | Medication                                  |
|             | Smoking status                              |
|             | Alcohol consumption                         |
|             | Physical activity                           |
|             | Body mass index ([weight in kilograms] / [height in meters$^2$]) |
|             | 6-Item Cognitive Impairment Test (6CIT)     |
|             | Impairment in activities of daily living (Rankin Scale, Barthel Index) |
|             | Blood pressure                              |
|             | Ankle-to-brachial index                     |
|             | Electrocardiogram                           |
| Fasting blood sample | Total cholesterol                          |
|             | Low-density lipoprotein cholesterol        |
|             | High-density lipoprotein cholesterol       |
|             | Triglycerides                               |
|             | Serum glucose                               |
|             | Hemoglobin A$_{1c}$                        |
|             | Creatinine                                  |
|             | Homocysteine                                |
|             | High-sensitivity C-reactive protein         |
| Ultrasound imaging | Intima-media thickness of common carotid artery |

Duplex ultrasonography of the carotid arteries was performed by 8 certified investigators. Mean common carotid artery intima-media thickness was measured as previously described$^{32}$ with the use of a computer-supported image analysis system (Sigmascan Pro 5.0).

Every 3 months after baseline, the GP measured the blood pressure of each participant, documented the current drug therapy, and reported whether vascular events had occurred in the preceding months. At intervals of 2, 4, and 6 years after baseline, a comprehensive follow-up examination was scheduled, in which a complete measurement of the risk factors was to be performed.

**Intervention**

The intervention consisted of the repeated, systematic identification of vascular risk factors and their subsequent treatment by the GP according to evidence-based guidelines. For each participant, an individual risk profile that included the Framingham Stroke Risk Profile$^{33}$ was reported to the GP, together with treatment goals and recommendations based on the current guidelines of the medical societies. A compact summary of the treatment recommendations was made available to the GPs in the form of a guideline brochure developed specially for this purpose; the brochure described the threshold values, target values, and therapy recommendations for arterial hypertension, dyslipidemia, and diabetes mellitus, as well as the therapy options for atrial fibrillation and depression. The GPs were trained in the use of the guidelines and were to orient the treatment of the participants according to these guidelines. The GPs also worked toward a change of the participants’ lifestyles, with the aims of smoking cessation, reduction of risky alcohol consumption, increase in physical activity, reduction of obesity, and improvement in nutrition according to the example of Mediterranean diet.$^{34}$

The study protocol was approved by the ethics committee of the medical faculty at the Technische Universität München. Written informed consent was obtained from each participant after complete information about the study had been provided.

**Outcome Measures**

The primary clinical end point chosen in the present study was the incidence of LTC dependence. In the year 1995, Germany introduced a statutory LTC insurance. Not only the elderly but also people of all age groups in need of care are eligible for benefits from the LTC insurance. These benefits are not coupled to any specific form of care but are furnished when care is given by relatives or other private caregivers as well as when care is given by professional ambulatory care services or by resident care in nursing homes.

To receive benefits from the LTC insurance, a persistent dependence on the assistance of caregivers must be proved. The health insurance fund’s medical service departments examine the applicants in their homes and assess the extent of their need for care in the areas of personal hygiene, eating, mobility, and housekeeping, according to legally defined uniform criteria.$^{35,36}$ Information on the number of patients with LTC dependence was made available to us by the LTC fund as aggregated data itemized according to sex and year of birth.

The secondary clinical end points used were the temporal changes in blood pressure, fasting serum glucose, hemoglobin A$_{1c}$, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, homocysteine, and body mass index after 2 and 4 years in the group of participants. Changes over 6 years were not analyzed in detail.
because for many participants the third follow-up examination laid beyond the legal maximum permissible study duration of 8 years for model projects of the health insurers.

Sample Size Calculation
We offered all policyholders in the district of Ebersberg the opportunity to participate in the program ("intention to treat"), although it was clear that only a certain percentage would enroll. We therefore attempted to estimate the least number of patients that would have to participate for a significant difference between all insured in the 2 districts to be observable. Under usual treatment, we expected ≈280 new cases of LTC dependence per calendar year in the district of Ebersberg. For the 5-year evaluation phase after recruitment of the participants, there thus would have resulted a total number of 1400 incident cases. With a level of significance of \( P < 0.05 \) and a statistical power of 80%, the expected number of 1400 incident cases would have to be reduced by \( \geq 88 \). Under the assumption that the intervention would lower the risk by 25%, the participation of \( \geq 2845 \) insurants in the intervention program was required for this reduction of 88 cases. Because it is difficult to judge beforehand whether the participants are at the same risk as the total population of insurants, we aimed for a participant number of substantially more than 3000.

Statistical Analyses
Statistical analyses were performed with SPSS for Windows, version 18.0. Data are described as means and standard deviations (mean±SD) or as numbers and percentages. For the analysis of secondary end points, we used repeated-measures analysis of variance. The \( \chi^2 \) test was used for the analysis of the primary end point (incidence of LTC dependence) on the basis of the aggregated data. LTC dependence comprises both those persons cared for in private homes and those accommodated in nursing homes.

On the basis of year of birth (1942–1946, 1937–1941, 1932–1936, 1927–1931, 1922–1926, 1917–1921, and \( \leq 1916 \)) and sex, we formed 14 subgroups in each district. For the reference district, we calculated the incidence rates of LTC dependence under usual medical care. In each subgroup, we divided the incident cases of LTC dependence that developed in the respective calendar year (numerator) by the number of insurants at the beginning of the year less the prevalent cases (denominator). We multiplied the resulting age- and sex-specific incidence rates by the number of insurants at risk in the intervention district and summed the products. Using this standardization, we obtained for each calendar year the number of incident cases that were to be expected if no intervention had taken place. This expected number of incident cases in the years 2004–2008 was compared to the number of new cases that in fact occurred in the intervention district. A \( P \) value of 0.05 was considered significant. To determine whether the risk of LTC dependence already differed between the districts during the recruitment period, we performed the same comparison for the years 2001–2003.

Analysis was by intention to treat. It is important to note that the expected number of LTC dependence cases was not calculated for the subsample of the study participants but rather for the totality of the insured in the intervention district, regardless of whether they had participated in the intervention program. That is, the incident cases of LTC dependence among all 11 317 insured in the district of Ebersberg were compared with the expected number, which was calculated according to the standardized rate from the reference district. The comparisons were carried out for both sexes together and separately for men and women. In addition, we calculated the standardized morbidity ratio as the quotient of the observed and expected incidence and its 95% confidence interval.

Furthermore, we compared the expected and the observed numbers of prevalent cases of LTC dependence for each individual calendar year. Prevalence rates in the reference district were calculated as the number of prevalent cases at the end of the year in the 14 subgroups formed according to age and sex (numerator) divided by the number of insured in these subgroups at the end of the year. The expected number of prevalent cases was determined, as in the case of incidence, through multiplication of the age- and sex-specific rates in the reference district by the number of insured in the intervention district.

Death represents a competing risk and was likewise compared for the entire period of the study. In the reference district, age- and sex-specific death rates were calculated for each calendar year by dividing the number of deaths in the course of each year (numerator) by the number of insured at the beginning of the year (denominator). The expected number of deaths in the intervention district resulted from transfer of the rates to the age and sex structure of the insured in the district of Ebersberg. This expected number was compared with the observed number of deaths.

Results
Baseline Data
The mean age of the 3908 participants in the intervention program was 67.7 years (standard deviation, 7.8); their ages ranged from 55 to 102 years. Half of the sample had lived for >50 years in the district of Ebersberg and 94% for \( \geq 10 \) years. Only 2.8% had not consulted the GP at all in the past year, and 19.5% consulted the GP less than once per quarter-year (Table 4).

Arterial hypertension (57.6%), dyslipidemia (43.9%), and diabetes mellitus (20.2%) were reported frequently by the GP.
### Table 4. Baseline Characteristics of Participants

| Characteristics | Men\(^*\) (n=1600) | Women\(^*\) (n=2308) | Total\(^*\) (n=3908) |
|-----------------|---------------------|----------------------|---------------------|
| Age, mean±SD, y | 66.7±7.1            | 68.5±8.1             | 67.7±7.8            |
| Duration of residency in district, mean±SD, y | 44.4±20.0 | 45.5±20.7 | 45.0±20.1 |
| GP consultation less than once a quarter | 391/1595 (24.5) | 476/2295 (20.7) | 867/3890 (22.3) |
| Inpatient treatment in past 12 months | 371/1597 (23.2) | 506/2301 (22.0) | 877/3898 (22.5) |
| Subjective health (fair or poor) | 603/1598 (37.7) | 849/2302 (36.9) | 1452/3900 (37.2) |
| Depression (Geriatric Depression Scale >5) | 146/1588 (9.2) | 233/2273 (10.3) | 379/3861 (9.8) |
| Cognitive impairment (6CIT >7) | 191/1599 (11.9) | 227/2307 (9.8) | 418/3906 (10.7) |
| Current smoking | 259/1598 (16.2) | 138/2307 (6.0) | 397/3905 (10.2) |
| No or little physical activity | 808/1597 (50.6) | 1301/2307 (56.4) | 2109/3904 (54.0) |
| Obesity (body mass index >30.0 kg/m\(^2\)) | 391/1600 (24.4) | 616/2307 (26.7) | 1007/3907 (25.8) |
| Systolic blood pressure | | | |
| ≥140 mm Hg | 795/1600 (49.7) | 1172/2308 (50.8) | 1967/3908 (50.3) |
| ≥160 mm Hg | 242/1600 (15.1) | 362/2308 (15.7) | 604/3908 (15.5) |
| Diastolic blood pressure | | | |
| ≥90 mm Hg | 405/1600 (25.3) | 542/2308 (23.5) | 947/3908 (24.2) |
| ≥100 mm Hg | 101/1600 (6.3) | 120/2308 (5.2) | 221/3908 (5.7) |
| Total cholesterol ≥6.21 mmol/L | 353/1591 (22.2) | 716/2283 (31.8) | 1081/3874 (27.9) |
| Low-density lipoprotein cholesterol ≥4.14 mmol/L | 275/1547 (17.8) | 501/2259 (22.2) | 776/3806 (20.4) |
| Triglycerides ≥2.26 mmol/L | 370/1589 (23.3) | 294/2283 (12.9) | 666/3872 (17.2) |
| Fasting serum glucose ≥7 mmol/L | 185/1590 (11.6) | 200/2284 (8.8) | 385/3874 (9.9) |
| Hemoglobin A\(_1c\) ≥6.5% | 189/1592 (11.9) | 251/2279 (11.0) | 440/3871 (11.4) |
| C-reactive protein ≥28.5 nmol/L | 544/1590 (34.2) | 870/2284 (38.1) | 1414/3874 (36.5) |
| Intima-media thickness of the common carotid artery ≥1 mm | 241/1385 (17.4) | 209/2001 (10.4) | 450/3386 (13.3) |
| Ankle-to-brachial-index <0.9 | 240/1522 (15.8) | 374/2228 (16.8) | 614/3750 (16.4) |
| Homocysteine >12 μmol/L | 92/1457 (6.3) | 156/2142 (7.3) | 248/3599 (6.9) |
| Diseases as reported by GP | | | |
| Dementia | 32/1589 (2.0) | 45/2301 (2.0) | 77/3890 (2.0) |
| Stroke | 67/1596 (4.2) | 68/2301 (3.0) | 135/3897 (3.5) |
| Chronic kidney disease | 69/1590 (4.3) | 53/2297 (2.3) | 122/3887 (3.1) |
| Alcohol abuse | 109/1583 (6.9) | 16/2303 (0.7) | 125/3886 (3.2) |
| Myocardial infarction | 115/1592 (7.2) | 47/2300 (2.0) | 162/3892 (4.2) |
| Transient ischemic attack | 79/1587 (5.0) | 95/2299 (4.1) | 174/3886 (4.5) |
| Atrial fibrillation | 94/1590 (5.9) | 91/2305 (3.9) | 185/3895 (4.7) |
| Peripheral vascular occlusion | 131/1564 (8.4) | 52/2269 (2.3) | 183/3833 (4.8) |
| Coronary heart disease | 264/1553 (17.0) | 216/2258 (9.6) | 480/3811 (12.6) |
| Depression | 136/1594 (8.5) | 366/2292 (16.0) | 502/3886 (12.9) |
| Diabetes mellitus | 373/1593 (23.4) | 416/2305 (18.0) | 789/3898 (20.2) |
| Dyslipidemia | 691/1578 (43.2) | 1003/2277 (44.0) | 1694/3855 (43.9) |
| Hypertension | 883/1593 (55.4) | 1359/2301 (59.1) | 2242/3894 (57.6) |

Data are expressed as number of participants / sample size (percentage) unless otherwise indicated.

*Because of missing values, sample sizes may differ.
Table 5. Changes in Risk Factors Between Baseline and First and Second Follow-Up Among Participants in the Intervention Program (n=2906 With Complete Data)

| Risk Factor                                    | Baseline (mean±SD) | Follow-Up I (mean±SD) | Follow-Up II (mean±SD) | F Value*† (df) | P     |
|------------------------------------------------|--------------------|----------------------|------------------------|----------------|-------|
| Systolic blood pressure, mm Hg                 | 139.4±17.8         | 137.1±17.4           | 136.9±17.1             | 31.2 (2, 2904) | <0.001|
| Diastolic blood pressure, mm Hg                | 82.2±9.4           | 80.7±8.9             | 80.0±9.2               | 57.0 (2, 2904) | <0.001|
| Fasting serum glucose, mmol/L                  | 5.30±1.65          | 5.07±1.51            | 5.05±1.64              | 47.1 (2, 2845) | <0.001|
| Hemoglobin A\(_1c\), %                         | 5.83±0.86          | 5.73±0.71            | 5.98±0.70              | 431.2 (2, 2826) | <0.001|
| Total cholesterol, mmol/L                      | 5.67±1.03          | 5.60±1.00            | 5.53±1.03              | 27.3 (2, 2844) | <0.001|
| Low-density lipoprotein cholesterol, mmol/L    | 3.44±0.90          | 3.32±0.87            | 3.25±0.89              | 62.2 (2, 2728) | <0.001|
| High-density lipoprotein cholesterol, mmol/L   | 1.51±0.41          | 1.56±0.41            | 1.59±0.42              | 119.1 (2, 2839) | <0.001|
| Triglycerides, mmol/L                          | 1.62±0.96          | 1.60±0.94            | 1.57±0.88              | 13.7 (2, 2842) | <0.001|
| Homocysteine, \(\mu\)mol/L                    | 7.36±3.32          | 6.47±3.71            | 6.62±4.40              | 67.6 (2, 2605) | <0.001|
| Body mass index, kg/m\(^2\)                    | 27.84±4.39         | 27.73±4.47           | 27.74±4.61             | 6.64 (2, 2898) | 0.002 |

*Repeated-measures analysis of variance.
†Degrees of freedom may differ because of missing data.

Many cases of disease were, however, unknown or insufficiently treated. Only 32.5% of the patients with known hypertension had baseline blood pressure in the target range of <140/90 mm Hg; in 41.9% of the cases, values up to 159/99 mm Hg were measured, and in 25.6%, blood pressure values exceeded 160/100 mm Hg. Furthermore, high blood pressure that previously had been unknown and untreated was diagnosed at baseline for 588 (15.0%) participants. For 393 (10.1%) participants, dyslipidemia was discovered for the first time, and for 65 (1.7%), previously undiscovered diabetes mellitus was identified.

Temporal Changes in Risk Factors

Among the participants in the intervention program, blood pressure, serum glucose, total cholesterol, low-density lipoprotein cholesterol, and triglycerides decreased, particularly during the first 2 years of the intervention, whereas high-density lipoprotein cholesterol increased. Hemoglobin A\(_1c\), homocysteine, and body mass index decreased only in the first 2 years after baseline and then increased again (Table 5). The changes were accompanied by increased drug use. The use of antihypertensive medications went up, from 57.4% at baseline to 70.6% at the second follow-up; the use of statins increased from 16.1% to 25.9%, and the use of anticoagulant and antiplatelet drugs rose from 31.0% to 43.5%.

Effects on LTC Dependence

Comparisons of incidence and prevalence of LTC dependence refer to the entire populations in the 2 districts. In the years 2004–2008, a total of 1240 incident cases of LTC dependence were observed in the intervention district. According to the data from the reference district, 1375 new cases were to be expected (Figure 3). The difference of 135 cases (−9.8%) is highly significant (\(\chi^2=13.25, df=1, P<0.001\)). The reduction of the incident cases of LTC dependence was significant for...
during the recruitment phase was 0.90 (95% confidence interval, 0.84–0.96). Among the men, the standardized morbidity ratio amounted to 0.90 (95% confidence interval, 0.85–0.95). Among the women, the standardized morbidity ratio was 0.905 (95% confidence interval, 0.82–0.99), and among the women, the standardized morbidity ratio was 0.90 (95% confidence interval, 0.84–0.96). During the baseline phase (2001–2003), no significant difference occurred (χ²=0.12, df=1, P=0.73). The number of prevalent cases of LTC dependence was lower than would have been expected without intervention (Figure 4). The difference was not significant at the end of the years 2004 (χ²=0.95, df=1, P=0.33) and 2005 (χ²=3.43, df=1, P=0.06). However, in the years 2006 (χ²=9.26, df=1, P=0.002), 2007 (χ²=9.90, df=1, P=0.002), and 2008 (χ²=12.37, df=1, P < 0.001), the prevalence was significantly lower than expected. On average, there were 80 (−7.8%) fewer prevalent cases than expected between 2004 and 2008 in the intervention district. During the recruitment phase, comprising the years 2001 (χ²=0.66, df=1, P=0.42), 2002 (χ²=0.02, df=1, P=0.89), and 2003 (χ²=0.12, df=1, P=0.73), we found no significant differences between the 2 districts.

During the baseline phase (2001–2003), there were no significant differences in death rate. In the intervention district, 1216 deaths occurred, whereas 1270 would have been expected (χ²=2.30, df=1, P=0.13). In the evaluation phase (2004–2008), on the other hand, the death rate in the intervention district was significantly reduced. In this period, only 1939 deaths occurred, whereas 2112 would have been expected (χ²=14.17, df=1, P < 0.001).

Discussion

To the best of our knowledge, INVADe is the first trial on the prevention of stroke and dementia in primary care that has demonstrated an effect of a tailored multidomain intervention on the incidence of LTC dependence. The results show that significantly fewer new cases of LTC dependence occurred among insured people living in the intervention district who previously had been unknown and untreated. This phenomenon stresses the preventive potential of systematic programs.37–39

Figure 4. Numbers of observed and expected prevalent cases of LTC dependence at the end of each of the years 2001 to 2008 in the intervention district (n=11 317 at the beginning of 2001).
It remains unclear whether the risk of dementia can be reduced by the intervention or whether the reduction in LTC dependence was caused by a reduction of the risk of vascular diseases or by completely different mechanisms. For stroke, an effect of primary prevention measures is supported by evidence from randomized trials. Because a transition from stroke to dementia is not rare, a reduced risk of post-stroke dementia is probable. It is, however, unknown whether the occurrence of degenerative dementias unrelated to the consequences of stroke can be prevented. Today, controlled trials do not yield sufficient evidence to develop effective intervention strategies against dementia at the population level.

Reviews found no convincing evidence for an effect of individual interventions, such as improved treatment of hypertension, dyslipidemia, and diabetes mellitus and other measures aimed at vascular factors. Multidomain interventions targeting multiple vascular risk factors increasingly are discussed as promising strategies for the prevention of degenerative dementias. It recently was estimated in a comprehensive review that the number of cases with Alzheimer’s dementia could be reduced by about half by the elimination of the 7 most important modifiable risk factors.

Our results are compatible with the hypothesis of a dementia-preventive effect of combined measures, but they can support it only indirectly. Several studies, such as the Dutch study Prevention of Dementia by Intensive Vascular Care (PreDIVA), the French Multidomain Alzheimer Preventive Trial (MAPT), and the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) (http://www.ClinicalTrials.gov identifier NCT01041989), which likewise use a combination of lifestyle modifications and treatment of classical vascular risk factors as intervention, are under way and will be able to analyze the specific relationships to incident cognitive disorders.

Our study had several strengths. It was embedded in medical primary care, and it used methods that can be applied easily in general practice and are suitable for broad use at the population level. The generalizability of the results seems to be high, given that the members of a statutory health insurance program represent a sample of the general population and nearly all GPs practicing in the intervention district participated in the trial. The large sample size ensured high statistical power, which was additionally increased by the long duration of the trial. The clinical end point of LTC dependence, which is highly relevant for health policy, was determined independently of our trial by a medical service in the framework of German statutory LTC insurance.

Some limitations of our trial need to be mentioned. Relative contributions of preventive measures cannot be assessed reliably in multidomain interventions. Because of the aging of the population, LTC dependence gains importance and is an outstanding public health issue per se; nevertheless, although LTC dependence is caused mainly by stroke and dementia, it is a less specific end point than disease because it can develop as the result of many different diseases. It thus remains unclear to what extent prevention of stroke and dementia contributed to the reduction of LTC dependence in our study.

A cluster randomization of the GP practices in the study area over a long period of 8 years was not feasible because of insurers’ freedom to choose their physicians. We thus decided to compare the study group with insurants from a structurally similar district in Upper Bavaria. We were able to show that the morbidity rates in the 2 populations of insured did not differ initially. Neither in the year 2000, which preceded the trial, nor in the years of participant recruitment, from 2001 through 2004, were there significant differences in the incidence and prevalence of LTC dependence. Death rate differences in the 2 districts contributed just as little to the explanation of the positive effects in the evaluation period. Before the trial and during baseline, there were no significant differences in the death rates. It was possible to exclude death acting as a competing risk for the occurrence of LTC dependence. Rather, the results indicate that even the death rate in the intervention district was reduced after the intervention.

Data on vascular risk factors could be obtained only for those insured who enrolled in the study. For the nonparticipants and for the insured from the reference district who could not be examined in person, these data were not available. A comparison between the insured in the 2 districts at baseline and after the intervention period with regard to these data was thus not possible. The comparison between the regions is based exclusively on the outcome data available to the health insurer.

If different trends in lifestyle or in the occurrence of other vascular risk factors had arisen in the 2 districts during the trial, they could have contributed to the differences in the outcome. We are, however, not aware of any social, economic, or health policy changes that could have affected the districts differently.

In conclusion, the results of our trial indicate that a multidomain intervention, intended to prevent stroke and dementia, can reduce the incidence of LTC dependence in a real-world setting. The public health impact of the 2 diseases possibly can be mitigated by improved control of vascular risk factors at the level of primary care. It will be an important task to investigate whether the effects are brought about primarily by the successful prevention of stroke or whether a multidomain intervention also contributes to the prevention of dementia.

Sources of Funding
This work was supported primarily by the health insurance company Allgemeine Ortskrankenkasse Bayern (AOK Bayern). Further support for different time periods came from the

DOI: 10.1161/JAHA.112.000786
German Stroke Foundation, Bayer Vital GmbH, Berlin-Chemie AG, Organon Pharmaceuticals, Ratiopharm GmbH, Sanofi-Synthelabo GmbH, and TEVA Pharmaceutical Industries Ltd.

Disclosures
Dr Bickel has received a speaker honorarium from Dr Willmar Schwabe Arzneimittel and receives research support from the German Federal Ministry of Education and Research. Dr Poppert has received research support from the German Federal Ministry of Economics and Technology; has received honoraria for lectures from EV3, Bristol-Myers Squibb, and Trommsdorf; and has received support for travel from Boehringer. Dr Förstl has received honoraria for presentations and meetings from Bayer, Janssen-Cilag, Eisai, General Electric, Lilly, Merz Pharma, Novartis, Nutricia, Pfizer, and Dr Willmar Schwabe Arzneimittel and serves on a scientific advisory board for Boehringer Ingelheim and Lundbeck. The remaining authors have no financial relationships with any organizations that might have an interest in the submitted work and no other relationships or activities that could appear to have influenced the submitted work.

References
1. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Fergunson TB, Ford E, Furie K, Gillespie C, Go A, Greenland K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Libaseth L, Marelli A, McDermott MM, Meiggs J, Mozaffarian D, Mussolinio M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Stafford R, Thom T, Wasserther-Moller S, Wong ND, Wylie-Rosett J. Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2010;121:e46–e215.
2. Brayne C, Gao L, Dewey M, Matthews FE. Dementia before death in ageing societies: the promise of prevention and the reality. PLoS Medicine. 2006;3:1922–1930.
3. Agüero-Torres H, von Strauss E, Vilianen M, Winblad B, Fratiglioni L. Institutionalization in the elderly: the role of chronic diseases and dementia: cross-sectional and longitudinal data from a population-based study. J Clin Epidemiol. 2001;54:795–801.
4. Prince M, Jackson J, eds. World Alzheimer Report 2009. Alzheimer’s Disease International, 2009.
5. Meerdink WJ, Bounevux P, Lorder JJ, Koopsmaan M, van der Maas DM. Demographic and epidemiological determinants of healthcare costs in Netherlands: cost of illness study. BMJ. 1998;317:111–115.
6. Wimo A, Winblad B, Jönsson L. The worldwide costs of dementia: estimates for 2009. Alzheimers Dement. 2010;6:98–103.
7. Carandang R, Seshadri S, Beiser A, Kelly-Hayes M, Kase CS, Kannel WB, Wolf PA. Trends in incidence, lifetime risk, severity, and 30-day mortality of stroke over the past 50 years. JAMA. 2006;292:2939–2946.
8. Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol. 2009;8:355–369.
9. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scauzfa M. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366:2112–2117.
10. O’Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, Rangajaran S, Islam S, Pais P, McMurray JJ, Mondo C, Damasceno A, Lopez-Jaramillo P, Hankey GJ, Dans AL, Yusoff K, Truelsen T, Diener H-C, Sacco RL, Ryglewicz D, Czlonkowska A, Weimer C, Wang X, Yusuf S. Risk factors for ischemic and intracerebral hemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376:112–123.
11. Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, Creager MA, Culumbras A, Ecket RH, Hart RG, Hinchey JA, Howard VJ, Jauch EC, Levine SR, Meisch JA, Moore WS, Nixon JV, Pearson TA. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:517–584.
12. World Health Organization. Prevention of Cardiovascular Disease: Guidelines for Assessment and Management of Cardiovascular Risk. Geneva: World Health Organization, 2007.
13. Kloppenborg RP, van den Berg E, Kappelle J, Biessels GJ. Diabetes and other vascular risk factors for dementia: which factor matters most? A systematic review. Eur J Pharmacol. 2008;585:97–108.
14. Beeri MS, Ravona-Springer R, Silverman JM, Haroutunian V. The effects of cardiovascular risk factors on cognitive compromise. Dialogues Clin Neurosci. 2009;11:201–212.
15. Oiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer’s disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci. 2009;11:111–128.
16. Larson EB. Prospects for delaying the rising tide of worldwide, late-life dementia. Int Psychogeriatr. 2010;22:1196–1202.
17. Middleton L, Yaffe K. Targets for the prevention of dementia. J Alzheimers Dis. 2010;20:915–924.
18. Daviglus ML, Bell CC, Berettini W, Bowen PE, Connolly ES, Cox NJ, Dunbar-JM, Granieri EC, Hunt G, McGarry K, Patel D, Potosky AL, Sanders-Bush E, Silberberg, Trevisan M. National Institutes of Health State-of-the-Science Conference Statement: preventing Alzheimer disease and cognitive decline. Ann Intern Med. 2010;153:176–181.
19. Kivipelto M, Ngandu T, Laatikkainen T, Winblad B, Soininen H. Tuomilehto J. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol. 2006;5:735–741.
20. Reitz C, Tang MX, Schupf N, Manly JJ, Mayeux R, Luchsinger JA. A summary risk score for the prediction of Alzheimer disease in elderly persons. Arch Neurol. 2010;67:835–841.
21. Elias MF, Sullivan LM, D’Agostino RB, Elias PK, Beiser A, Au R, Seshadri S, DeCarli C, Wolf PA. Framingham stroke risk profile and lowered cognitive performance. Stroke. 2004;35:404–409.
22. Llewellyn DJ, Lang IA, Xie J, Huppert FA, Melzer D, Langa KM. Framingham stroke risk profile and poor cognitive function: a population-based study. BMC Neurol. 2008;8:12. doi: 10.1186/1471-2377-8-12.
23. Coley N, Andreux S, Gardette V, Gillette-Guyonnet S, Sanz C, Vellas B, Grand A. Dementia prevention: methodological explanations for inconsistent results. Epidemic Rev. 2008;30:35–46.
24. Stephan BCM, Brayne C. Vascular factors and prevention of dementia. Int Rev Psychiatry. 2008;20:344–356.
25. Lighthart SA, Moll van Charante EM, van Goor WA, Richard E. Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review. Vasc Health Risk Manag. 2010;6:775–785.
26. de la Torre JC. Vascular risk factor detection and control may prevent Alzheimer’s disease. Ageing Res Rev. 2010;9:218–225.
27. Yesavage JA, Sheikh JI. A Geriatric Depression Scale (GDS): recent evidence and development of a shorter version. Clin Gerontol. 1986;5:165–173.
28. Brooke P, Bullock R. Validation of a 6 item cognitive impairment test with a view to primary care usage. Int J Geriatr Psychiatry. 1999;14:936–940.
29. Egen T, Sander D, Huntgeburth U, Poppel H, Förstl H, Bickel H. Physical activity and incident cognitive impairment in elderly persons: the INVADE study. Arch Intern Med. 2010;170:186–193.
30. Bonita R, Beaglehole R. Modification of Rankin Scale: Recovery of motor function after stroke. Stroke. 1998;19:1497–1500.
31. Mahoney FI, Barthel D. Functional evaluation: the Barthel index. Md State Med J. 1965;14:61–65.
32. Sander D, Kukla C, Klingenhofer J, Winbeck K, Conrad B. Relationship between circadian blood pressure patterns and progression of early carotid arteriosclerosis: A 3-year follow-up study. Circulation. 2000;102:1536–1541.
33. Wolf PA, D’Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke. 1991;22:312–318.
34. Scarpace A, Luchsinger JA, Schupf N, Brickman AM, Cosentino S, Tang MX, Stern Y. Physical activity, diet, and risk of Alzheimer disease. JAMA. 2009;302:627–637.
35. Wahner-Roedler DL, Knuth P, Luches H-R. The German Pflegeversicherung: putting a social insurance model into practice. Milbank Q. 2000;78:375–401.
36. Wolf-Maier K, Cooper RS, Banegas JR, Giampoli S, Hense HW, Joffres M, Kasparin M, Poulter N, Primastella P, Rodriguez-Arteaga F, Stegmayr B, Thamm M, Tuomilehto J, Vanzuzzo D, Vescio F. Hypertension prevalence and blood
38. Centers for Disease Control and Prevention (CDC). Vital signs: prevalence, treatment, and control of hypertension—United States, 1999–2002 and 2005–2008. MMWR Morb Mortal Wkly Rep. 2011;60:103–108.

39. Centers for Disease Control and Prevention (CDC). Vital signs: prevalence, treatment, and control of high levels of low-density lipoprotein cholesterol—United States, 1999–2002 and 2005–2008. MMWR Morb Mortal Wkly Rep. 2011;60:109–114.

40. Straus SE, Majumdar SR, McAlister FA. New evidence for stroke prevention. Scientific review. JAMA. 2002;288:1388–1395.

41. Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol. 2009;8:1006–1018.

42. Ukraintseva S, Sloan F, Arbeev K, Yashin A. Increasing rates of dementia at time of declining mortality from stroke. Stroke. 2006;37:1155–1159.

43. McGuinness B, Todd S, Passmore P, Bullock R. Systematic review: blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. J Neurol Neurosurg Psychiatry. 2008;79:4–5.

44. McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database Syst Rev. 2009;(2):CD003160. doi:10.1002/14651858.CD003160.pub2.

45. Evans JG, Sastre AA. Effect of the treatment of Type II diabetes mellitus on the development of cognitive impairment and dementia. Cochrane Database Syst Rev. 2003;(1):CD003804. doi:10.1002/14651858.CD003804.

46. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet Neurol. 2011;10:819–828.

47. Richard E, van den Heuvel E, Moll van Charante EP, Achthoven L, Vermeulen M, Bindels PJ, van Gool WA. Prevention of dementia by intensive vascular care (PreDIVA): a cluster-randomized trial in progress. Alzheimer Dis Assoc Disord. 2009;23:198–204.

48. Gillette-Guyonnet S, Andrieu S, Dartigues J-F, Touchon J, Vellas B; MAPT Study Group. Commentary on “A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.” The Multidomain Alzheimer Preventive Trial (MAPT): a new approach to the prevention of Alzheimer’s disease. Alzheimers Dement. 2009;5:114–121.